ASCO 2019
ASCO 2019
Advertisement
Victoria SochaASCO 2019 | October 31, 2019
Renal cell carcinoma (RCC) is the most common histologic type of urologic cancer. Worldwide, the age-standardized rate ...
Read More
Victoria SochaASCO 2019 | October 24, 2019
Several therapeutic combinations of immune-oncology (IO) plus vascular endothelial growth factor (VEGF) regimens have ...
Victoria SochaASCO 2019 | April 25, 2023
Immune Checkpoint Therapy plus Cytoreductive Surgery in mRCC ...
Victoria SochaASCO 2019 | April 25, 2023
Immune Checkpoint Inhibitor Response in Patients with mRCC ...
Victoria SochaASCO 2019 | October 14, 2019
Costs of episodes of care in metastatic renal cell carcinoma (mRCC) vary by therapy and treatment decisions have ...
Victoria SochaASCO 2019 | October 10, 2019
Ipilimumab plus nivolumab is a first-line combination treatment option in patients with metastatic renal cell carcinoma ...
Victoria SochaASCO 2019 | October 7, 2019
Nivolumab plus ipilimumab was proven superior to sunitinib in objective response rate and overall survival in patients ...
Victoria SochaASCO 2019 | September 26, 2019
Ronan Flippot, MD, MSc, and colleagues conducted a multicenter, open-label, single arm phase 2 trial of atezolizumab ...
Victoria SochaASCO 2019 | September 25, 2019
In previous clinical trials of patients with advanced renal cell carcinoma (aRCC), including CheckMate 214, patients ...
Victoria SochaASCO 2019 | September 16, 2019
The prospective, multicenter study, PAZOREAL,  is designed to examine the effectiveness, defined as primary time on ...
Victoria SochaASCO 2019 | September 12, 2019
In the phase 3 KEYNOTE-426 trial, patients with metastatic renal cell carcinoma (mRCC) had significant improvement in ...
Victoria SochaASCO 2019 | April 25, 2023
In patients with renal cell carcinoma (RCC) with low tumor burden or slow growing disease, active surveillance is a ...
Victoria SochaASCO 2019 | September 5, 2019
Researchers reported updated results from cohort A in the KEYNOTE-427 trial during a poster session at the ASCO 2019 ...
Victoria SochaASCO 2019 | September 3, 2019
Renal function in a large, clinically assessed cohort of childhood cancer survivors was analyzed using data from the St. ...
Victoria SochaASCO 2019 | August 29, 2019
Treatment for advanced renal cell carcinoma (aRCC) commonly includes immune-oncology therapies and tyrosine kinase ...
Victoria SochaASCO 2019 | August 29, 2019
There are few data available on gender-related clinical outcomes and safety of treatment of with immune check point ...
Victoria SochaASCO 2019 | April 20, 2023
Patients with renal cell carcinoma (RCC) or urothelial carcinoma (UC) with clinically significant autoimmune disorders ...
DocWire News EditorsASCO 2019 | June 11, 2019
Addition of Apalutamide to ADT Improves Survival in Castration-Resistant Prostate Cancer ...
DocWire News EditorsASCO 2019 | June 6, 2019
In previously reported data from the randomized, placebo-controlled, phase III SPARTAN study, researchers found that the ...
DocWire News EditorsASCO 2019 | April 7, 2023
The standard of care for smoldering multiple myeloma (SMM), a precursor to MM, is observation. However, a 2015 study ...
Advertisement
Advertisement
Advertisement
Latest News

April 29, 2024